These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16254685)

  • 1. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
    Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
    Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
    Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
    Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
    Zhang M; Xu E; Zhang J; Chen X
    Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
    Lambros MB; Natrajan R; Geyer FC; Lopez-Garcia MA; Dedes KJ; Savage K; Lacroix-Triki M; Jones RL; Lord CJ; Linardopoulos S; Ashworth A; Reis-Filho JS
    Mod Pathol; 2010 Oct; 23(10):1334-45. PubMed ID: 20543821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
    Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
    Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H; Chen R; Li W; Xu L; Xu L
    Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
    Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
    Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization.
    Mu K; Li L; Yang Q; Zhang T; Gao P; Meng B; Liu Z; Wang Y; Zhou G
    Histopathology; 2011 Mar; 58(4):601-7. PubMed ID: 21401699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
    Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
    Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.
    Wazir U; Jiang WG; Yasaei H; Linne H; Newbold RF; Mokbel K
    Anticancer Res; 2013 May; 33(5):2185-9. PubMed ID: 23645774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.
    Orsetti B; Nugoli M; Cervera N; Lasorsa L; Chuchana P; Rougé C; Ursule L; Nguyen C; Bibeau F; Rodriguez C; Theillet C
    Br J Cancer; 2006 Nov; 95(10):1439-47. PubMed ID: 17060936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
    Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
    Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Inokuchi M; Sawada-Kitamura S; Kawashima H; Nakamura R; Oyama T; Dobashi Y; Ooi A
    Pathol Int; 2014 May; 64(5):231-6. PubMed ID: 24888777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.